These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37975611)

  • 1. Effect of the Phosphate Binder Sevelamer Carbonate on the Bioavailability of Enarodustat, an Oral Erythropoiesis Stimulating Agent.
    Pai SM; Yamada H
    Clin Pharmacol Drug Dev; 2024 Jan; 13(1):111-116. PubMed ID: 37975611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the Phosphate Binders Sevelamer Carbonate and Calcium Acetate on the Pharmacokinetics of Roxadustat After Concomitant or Time-separated Administration in Healthy Individuals.
    Groenendaal-van de Meent D; Kerbusch V; Barroso-Fernandez B; den Adel M; van Dijk J; Golor G; Schaddelee M
    Clin Ther; 2021 Jun; 43(6):1079-1091. PubMed ID: 33962762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, improves iron utilization and anemia of inflammation: Comparative study against recombinant erythropoietin in rat.
    Shinozaki Y; Fukui K; Kobayashi H; Yoshiuchi H; Matsuo A; Matsushita M
    Eur J Pharmacol; 2021 May; 898():173990. PubMed ID: 33657422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial.
    Akizawa T; Nangaku M; Yamaguchi T; Arai M; Koretomo R; Matsui A; Hirakata H
    Am J Nephrol; 2019; 49(2):165-174. PubMed ID: 30699415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enarodustat to treat anemia in chronic kidney disease.
    Fukui K; Tanaka T; Nangaku M
    Drugs Today (Barc); 2021 Aug; 57(8):491-497. PubMed ID: 34405206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence.
    Fujikawa R; Nagao Y; Fujioka M; Akizawa T
    Ther Apher Dial; 2022 Aug; 26(4):679-693. PubMed ID: 35218616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial.
    Akizawa T; Nangaku M; Yamaguchi T; Arai M; Koretomo R; Maeda K; Miyazawa Y; Hirakata H
    Nephron; 2019; 143(2):77-85. PubMed ID: 31117088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.
    Ruggiero B; Trillini M; Tartaglione L; Rotondi S; Perticucci E; Tripepi R; Aparicio C; Lecchi V; Perna A; Peraro F; Villa D; Ferrari S; Cannata A; Mazzaferro S; Mallamaci F; Zoccali C; Bellasi A; Cozzolino M; Remuzzi G; Ruggenenti P; Kohan DE;
    Am J Kidney Dis; 2019 Sep; 74(3):338-350. PubMed ID: 31027883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 3 Study of Enarodustat (JTZ-951) in Japanese Hemodialysis Patients for Treatment of Anemia in Chronic Kidney Disease: SYMPHONY HD Study.
    Akizawa T; Nangaku M; Yamaguchi T; Koretomo R; Maeda K; Miyazawa Y; Hirakata H
    Kidney Dis (Basel); 2021 Nov; 7(6):494-502. PubMed ID: 34901195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the effect of lanthanum carbonate hydrate on the pharmacokinetics of roxadustat in non-elderly healthy adult male subjects.
    Shibata T; Nomura Y; Takada A; Aoki S; Katashima M; Murakami H
    J Clin Pharm Ther; 2018 Oct; 43(5):633-639. PubMed ID: 29981285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enarodustat Treatment for Renal Anemia in Patients With Non-dialysis Chronic Kidney Disease.
    Mima A
    In Vivo; 2023; 37(2):825-829. PubMed ID: 36881056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
    Fukui K; Shinozaki Y; Kobayashi H; Deai K; Yoshiuchi H; Matsui T; Matsuo A; Matsushita M; Tanaka T; Nangaku M
    Eur J Pharmacol; 2019 Sep; 859():172532. PubMed ID: 31301309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Mass Balance Study of
    Pai SM; Connaire J; Yamada H; Enya S; Gerhardt B; Maekawa M; Tanaka H; Koretomo R; Ishikawa T
    Clin Pharmacol Drug Dev; 2020 Aug; 9(6):728-741. PubMed ID: 31876104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol.
    Pierce D; Hossack S; Poole L; Robinson A; Van Heusen H; Martin P; Smyth M
    Nephrol Dial Transplant; 2011 May; 26(5):1615-21. PubMed ID: 20921291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Drug-Drug Interaction Potential of Enarodustat (JTZ-951) Using a Cytochrome P450 Probe Cocktail.
    Pai SM; Yamada H; Murata H
    Clin Pharmacol Drug Dev; 2023 Jul; 12(7):667-682. PubMed ID: 37269147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
    Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodialysis Clearance of Enarodustat (JTZ-951), an Oral Erythropoiesis Stimulating Agent, in Patients with End-Stage Renal Disease.
    Pai SM; Yamada H
    Clin Pharmacol Drug Dev; 2021 May; 10(5):463-470. PubMed ID: 33788422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
    Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
    Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Carcinogenic Potential of Enarodustat (JTZ-951), a Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor, in 26-Week Tg.rasH2 Mouse Study and 2-Year Sprague-Dawley Rat Study.
    Kemmochi Y; Toyoda K; Ishida T; Yasui Y; Shoda T
    Int J Toxicol; 2023 Dec; 42(6):489-503. PubMed ID: 37480334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thorough QT/QTc Evaluation of the Cardiac Safety of Enarodustat (JTZ-951), an Oral Erythropoiesis-Stimulating Agent, in Healthy Adults.
    Pai SM; Yamada H; Kleiman RB; Zhuo R; Huang QM; Koretomo R
    Clin Pharmacol Drug Dev; 2021 Aug; 10(8):884-898. PubMed ID: 34159762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.